Articles in scientific journals, books, periodicals and online publications
2024:
184.) Subramani PG, Fraszczak J, Helness A, Patenaude AM, Estall J, Möröy T and Di Noia JM.
Conserved role of hnRNPL in alternative splicing of epigenetic modifiers enables B cell activation.
EMBO Rep. 2024 Jun;25(6):2662-2697. doi: 10.1038/s44319-024-00152-3.
183.) Huang Q, Curio S, Dight J, Schreuder J, Chaudhry MZ, Liao Y, Shi W, Seillet C, Jacquelot N, Möröy T, Belz GT.
GFI1B determines specificity of lung tissue resident multipotent ILC.
Science Immunology. 2024, May 31;9(95):eadj2654. doi: 10.1126/sciimmunol.adj2654.
2023:
182.) Frank D, Patnana PK, Vorwerk J, Mao L, Gopal LM, Jung N, Henning T, Frenz JM, Kuppusamy M, Autry R, Wei L, Sun K, Ahmed HMM, Künstner A, Busch H, Müller H, Hutter S, Hoermann G, Liu L, Xie X, Y Al-Matary Y, Nimmagadda SC, Cano FC, Heuser M, Thol F, Göhring G, Steinemann D, Thomale J, Leitner T, Fischer A, Rad R, Vick B, Jeremias I, Röllig C, Stölzel F, Altmann H, Kunadt D, Berdel WE, Hüve J, Neumann F, Klingauf J, Calderon V, Opalka B, Dührsen U, Rosenbauer F, Dugas M, Varghese J, Reinhardt HC, von Bubnoff N, Möröy T, Lenz G, Batcha AMN, Giorgi M, Selvam M, Wang E, McWeeney SK, Tyner JW, Mann M, Jayavelu AK and Khandanpour C.
Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Blood, 2023, Dec 21;142(25):2175-2191. doi: 10.1182/blood.2022015752.
181.) Möröy T, Khandanpour C.
Editorial, Frontiers in Oncology Series “New Emerging Functions of Transcription Factors and RNA-Binding Proteins in the Development of Hematological Malignancies”.
Frontiers in Oncology, 2023 Aug 1;13:1256461. doi: 10.3389/fonc.2023.1256461.
180.) Lacroix M, Beauchemin H, Khandanpour C, Möröy T.
The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma
Frontiers in Oncology, 2023, Mar 24;13:1148936. doi: 10.3389/fonc.2023.1148936.
2022:
179.) Lacroix M, Beauchemin H, Möröy T.
DDX3: a relevant therapeutic target for lymphoma?
Expert Opin Ther Targets, 2022 Dec;26(12):1037-1040. doi: 10.1080/14728222.2022.2166830.
178.) Winkler R, Mägdefrau AS, Kleemann M, Beyer M, Linke K, Hansen L, Schaffer AM, Hoffmann ME, Poepsel S, Heyd F, Beli P, Möröy T, Mahboobi S, Krämer OH, Kosan C
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
Oncogene, 2022, Sep;41(40):4560-4572. doi: 10.1038/s41388-022-02450-3.
177.) Lacroix M, Beauchemin H, Fraszczak J, Chen R, Shooshtarizadeh P, Möröy T.
The X-linked helicase DDX3X is required for lymphoid differentiation and MYC-driven lymphomagenesis
Cancer Research, 2022, Sep 2;82(17):3172-3186. doi: 10.1158/0008-5472.CAN-21-2454.
176.) Piskor EM, Ross J, Möröy T, Kosan C.
Myc-interacting zinc finger protein 1 (Miz 1) is essential to maintain homeostasis and immunocompetence of the B cell lineage
Biology (Basel). 2022 Mar 24;11(4):504. doi: 10.3390/biology11040504
2021:
173.) Fraszczak J, Möröy T.
The transcription factors GFI1 and GFI1B as modulators of the innate and acquired immune response
Advances in Immunol. 2021;149:35-94. doi: 10.1016/bs.ai.2021.03.003. Epub 2021 Apr 23.
172.) Ross J, Miron CE, Plescia J, Laplante P, McBride K, Moitessier N, Möröy T.
Targeting MYC: from understanding its biology to drug discovery
Eur J. Med Chem., 2021 Mar 5;213:113137. doi: 10.1016/j.ejmech.2020.113137.
2020:
171.) Beauchemin H, Möröy T.
Multifaceted actions of GFI1 and GFI1B in hematopoietic stem cell self-renewal and lineage commitment
Frontiers in Genetics, 2020, Oct 26, 11:591099. doi: 10.3389/fgene.2020.591099
170.) Arman K, Möröy T.
Crosstalk between MYC and lncRNAs in hematological malignancies
Frontiers in Oncology, 2020, Oct 8, 10:579940. doi: 10.3389/fonc.2020.579940
169.) Beauchemin H, Shooshtarizadeh P, Pinder J, Dellaire G, Möröy T.
Dominant negative Gfi1b mutations cause moderate thrombocytopenia and an impaired stress thrombopoiesis associated with mild erythropoietic abnormalities in mice
Haematologica, 2020, Oct 1;105(10):2457-2470. doi: 10.3324/haematol.2019.222596.
2019:
168.) Khandanpour C, Möröy T.
Role of GFI1 in epigenetic regulation of MDS and AML pathogenesis: mechanisms and therapeutic implications
Frontiers in Oncology, 2019, Aug 27; 9:824. doi: 10.3389/fonc.2019.00824.
167.) Ross J, Rashkovan M, Fraszczak J, Joly-Beauparlant C, Vadnais C, Winkler R, Droit A, Kosan C, Möröy T.
Deletion of the Miz-1 POZ domain increases efficacy of cytarabine treatment in T- and B-ALL/lymphoma mouse models.
Cancer Research, 2019, Aug 15;79(16):4184-4195. doi: 10.1158/0008-5472.CAN-18-3038.
166.) Vadnais C, Chen R, Fraszczak J, Hamard PJ, Manfredi J and Möröy T.
A novel regulatory circuit between p53 and GFI1 controls induction of apoptosis in T cells.
Scientific Reports, 2019, Apr 19;9(1):6304. doi: 10.1038/s41598-019-41684-2
165.) Shooshtarizadeh P, Helness A, Vadnais C, Brouwer N, Beauchemin H, Chen R, Bagci H, Staal FJT, Côté JF, Möröy T.
Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes
Nature Communications, 2019, Mar 20;10(1):1270. doi: 10.1038/s41467-019-09273-z.
164.) Fraszczak J, Vadnais C, Rashkovan M, Ross J, Chen R, Beauchemin H, Grapton, Khandanpour C and Möröy T.
Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice
Leukemia, 2019, Jan; 33(1):110-121. doi: 10.1038/s41375-018-0166-1.
2018:
163.) Vadnais C, Möröy T.
GFI1’s role in DNA repair suggests implications for tumour cell response to treatment
Cell Stress, 2018, Vol. 2, No. 8, pp. 213 – 215. doi: 10.15698/cst2018.07.149.
162.) Marneth AE, Botezatu L, Hönes JM, Israël JCL, Schütte J, Lams RL, Bergevoet SM, Groothuis L, Mandoli A, Lo MC, Martens JH, Huls G, Jansen JH, Dührsen U, Berg T, Möröy T, Wichmann C, Zhang DE, an der Reijden BA, and Khandanpour C.
GFI1 is required for RUNX1/ETO positive acute myeloid leukemia
Hematologica, 2018 Sep; 103(9): e395–e399. doi: 10.3324/haematol.2017.180844.
161.) Vadnais C, Chen R, Fraszczak J, Yu Z, Boulais J, Pinder J, Frank D, Khandanpour C, Hébert J, Dellaire G, Côté JF, Richard S, Orthwein A, Drobetsky E, Möröy T.
GFI1 facilitates efficient DNA repair by regulating PRMT1 dependent methylation of MRE11 and 53BP1
Nature Communications, 2018, Apr 12;9(1):1418. 10.1038/s41467-018-03817-5
2017:
160.) Beauchemin H, Shooshtarizadeh P, Vadnais C, Vassen L, Pastore Y and Möröy T.
Gfi1b controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes
Hematologica, 2017, Mar;102(3):484-497. doi: 10.3324/haematol.2016.150375.
159.) Hansen M, Varga E, Wüst T, Brouwer N, Beauchemin H, Mellink C, van der Kevie-Kersemaekers AM, Möröy T, van der Reijden B, von Lindern M, van Akkeren E.
Generation and characterization of human iPSC line MML-6838-Cl2 from mobilized peripheral blood derived megakaryoblasts
Stem Cell Research, 2017, (Jan)18: 26-28. doi: 10.1016/j.scr.2016.12.004.
158.) Fraszczak J, Möröy T.
The role of the transcriptional repressor growth factor independent 1 in the formation of myeloid cells
Curr. Opinions in Hematology, 2017, Jan;24(1):32-37. doi: 10.1097/MOH.0000000000000295.
2016:
157.) Möröy T.
The power of Translation.
World Health Summit Yearbook, 2016 (oct), 78-79.
156.) Fraszczak, Helness A, Chen R, Vadnais C, Robert F, Khandanpour C, Möröy T.
Threshold Levels of Gfi1 Maintain E2A Activity for B Cell Commitment via Repression of Id1
PlosOne, 2016, Jul 28;11(7):e0160344. doi: 10.1371/journal.pone.0160344.
155.) Gaudreau MC, Grapton D, Helness A, Vadnais C, Fraszczak J, Shooshtarizadeh P, Wilhelm B, Robert F, Heyd F, Möröy T.
Heterogeneous Nuclear Ribonucleoprotein L is required for the survival and functional integrity of murine hematopoietic stem cells
Sci. Reports, 2016, June 7; 6: 27379. doi: 10.1038/srep27379.
154.) Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hönes JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schütte J, Giebel B, Görgens A, Heuser M, Medyouf H, Maciejewski J, Dührsen U, Möröy T*, Khandanpour C*. (co-senior author).
Epigenetic therapy impedes leukemia progression in patients carrying the GFI136N AML predisposing gene
Exp Hematol., 2016, Aug;44(8):713-726.e14. doi: 10.1016/j.exphem.2016.05.004.
153.) Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, Bert van der Reijden B, Marneth A, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Cazzola M, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.
GFI136N as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
Exp Hematol., 2016, Jul;44(7):590-595.e1. doi: 10.1016/j.exphem.2016.04.001.
152.) Thambyrajah R, Mazan M, Patel R, Moignard V, Stefanska M, Marinopoulou E, Li Y, Lancrin C, Clapes T, Möröy T, Robin C, Miller C, Cowley S, Goettgens B, Kouskoff V, and Lacaud G.
GFI1 proteins orchestrate the emergence of Haematopoietic Stem Cells through recruitment of LSD1
Nat Cell Biol., 2016, Jan;18(1):21-32. doi: 10.1038/ncb3276.
151.) Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G, Dührsen U, Maciejewski J, Möröy T*, Khandanpour C*. (co-senior author).
GFI1 as a novel prognostic and therapeutic factor for AML/MDS
Leukemia. 2016, June 30(6): 1237-45. doi: 10.1038/leu.2016.11.